Abcuro
Abcuro was launched in 2016 and is currently working to develop a new generation of immunomodulatory therapeutics for treating both autoimmunity and cancer. They are based out of Newton, Massachusetts.
Last updated on
About Abcuro
Estimated Revenue
$1M-$10MEmployees
11-50Funding / Mkt. Cap
$215MCategory
Sector
Health CareIndustry Group
Pharmaceuticals, Biotechnology & Life SciencesIndustry
PharmaceuticalsSIC Code
87NAICs Code
325414Location
City
NewtonState
MassachusettsCountry
United StatesTech Stack (32)
